Johnson & Johnson outlines double-digit growth ambition by end of decade as 2026 sales set to surpass $100B
Earnings Call Insights: Johnson & Johnson (JNJ) Q4 2025 Joaquin Duato, CEO & Chairman, opened by emphasizing, "We...
Tag: JNJ
J&J talc litigation advances as expert testimony is approved
A court-designated special master has recommended that plaintiffs accusing Johnson & Johnson (JNJ) of marketing...
Earnings Snapshot: Johnson & Johnson tops Q4 estimates; initiates FY26 outlook above forecast
*Other Operating Data Consensus Source: Bloomberg Is Johnson & Johnson A Dividend Stock, Or Something Else? Johnson...
J&J posts Q4 revenue beat as Pharma, MedTech units outperform
Johnson & Johnson (JNJ), the earnings bellwether for the healthcare sector, reported better-than-expected revenue for Q4...
Johnson & Johnson Non-GAAP EPS of $2.46 in-line, revenue of $24.6B beats by $440M
Johnson & Johnson press release (JNJ): Q4 Non-GAAP EPS of $2.46 in-line. Revenue of $24.6B (+9.3% Y/Y) beats by $440M....
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials
Arcellx (ACLX) and Legend Biotech (LEGN) traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of...
Johnson & Johnson Q4 Preview: Strength in core portfolio keeps analysts bullish
Johnson & Johnson (JNJ) is expected to announce a 21% jump in its fourth quarter earnings on January 21, before the...
New research suggests no link between autism and Tylenol use in pregnancy
A newly published analysis indicates that there is no link between autism or other neurodevelopmental disorders and the use...
J&J’s Tecvayli shows promise as a second-line multiple myeloma treatment
New phase 3 data found that Johnson & Johnson's (JNJ) Tecvayli (teclistamab) as monotherapy led to better...